Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Incidence of R/R DLBCL Lower Than Expected in Population-Based Study
Key clinical point: The 5-year cumulative incidence of primary refractory disease and relapse (R/R) in patients with diffuse large B-cell lymphoma (DLBCL) who were treated with curative intent was lower than in previously published reports.
Major finding: The 5-year cumulative incidence of primary refractory disease and relapse in a population-based setting was 21%. The 2-year cumulative incidence of CNS progression/relapse when accounting for competing risks was low at 2.9%.
Study details: A population-based study of 4,202 patients with a primary diagnosis of DLBCL in 2007-2014 and followed until October 31, 2017.
Disclosures: The study was funded by the Karolinska Institutet and Janssen Pharmaceuticals as well as the Swedish Cancer Society.
Harrysson S et al. ASH 2019. Abstract 399.